KAZIA THERAPEUTICS LTD
KZIA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KZIA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KZIA
Kazia Therapeutics Ltd is a clinical-stage oncology company developing two small-molecule drug candidates, Paxalisib (PI3K/Akt/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor), with a going-concern uncertainty and limited cash resources.
Key risk: Going-concern uncertainty
Market Cap
$155.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 1 clinical trial for KAZIA THERAPEUTICS LTD.
Kazia Therapeutics Ltd is a clinical-stage oncology company developing two small-molecule drug candidates, Paxalisib (PI3K/Akt/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor), with a going-concern uncertainty and limited cash resources.
- Lead programs include Paxalisib (PI3K/Akt/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor) [sec · filed 2025-11-07].
- As of 2025-12-31, the company reported cash & equivalents of $69.5M, no revenue, and a net loss of -$20.7M [sec].
- As of 30 June 2025, accumulated losses were A$134.8M and cash was A$4.3M [sec · filed 2025-11-07].
- There is substantial doubt about the company's ability to continue as a going concern [sec · filed 2025-11-07].
- Plans for a Phase 2 trial are on hold while exploring regional and strategic partnerships [sec · filed 2025-11-07].
What works
- Paxalisib targets the clinically validated PI3K/Akt/mTOR pathway in oncology [sec · filed 2025-11-07].
- The company has two product candidates in clinical trials, providing multiple shots on goal [sec · filed 2025-11-07].
- Anticipated milestones for fiscal year 2026 include completion of enrollment in a Phase 1b trial of Paxalisib in TNBC and publication of expanded-access data [sec · filed 2025-11-07].
What to weigh
- The company has a going-concern uncertainty and expects to consume cash and incur operating losses for the foreseeable future [sec · filed 2025-11-07].
- As of 30 June 2025, accumulated losses were A$134.8M, and cash was only A$4.3M (though later reported $69.5M as of 2025-12-31) [sec · filed 2025-11-07].
- Failure of either product candidate to show benefit could materially and adversely affect business continuity [sec · filed 2025-11-07].
- The company may not be able to secure additional funding on acceptable terms, which could force delays or reductions in clinical programs [sec · filed 2025-11-07].
From the filings
Quoted directly from source documents.
Going-concern uncertainty
“There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.”
SEC filings · November 7, 2025
Lead programs are Paxalisib and EVT801
“The Company's lead programs include Paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K/Akt/mTOR pathway, and EVT801, a small molecule selective inhibitor of vascular endothelial growth factor receptor 3 ("VEGFR3").”
SEC filings · November 7, 2025
Accumulated losses as of 30 June 2025
“as of 30 June 2025, we had accumulated losses of A$134.8 million.”
SEC filings · November 7, 2025
Phase 2 trial plans on hold
“Plans for phase 2 clinical trial are on hold while exploring regional and strategic partnerships.”
SEC filings · November 7, 2025
Risks & what to watch (4)›
Key risks
- Going-concern uncertainty — Substantial doubt about ability to continue as a going concern may hinder financing [sec · filed 2025-11-07].
- Clinical trial failure risk — Failure of either product candidate to show benefit could materially and adversely affect business [sec · filed 2025-11-07].
- Need for additional funding — Company expects to consume cash and will need additional capital; may not obtain on acceptable terms [sec · filed 2025-11-07].
- No revenue in foreseeable future — Company does not anticipate generating revenue from product sales for the foreseeable future [sec · filed 2025-11-07].
What to watch
- Completion of enrollment in the Phase 1b trial of Paxalisib in TNBC, anticipated in fiscal year 2026 [sec · filed 2025-11-07].
- Preliminary analyses from expanded-access Paxalisib data in TNBC, expected in fiscal year 2026 [sec · filed 2025-11-07].
- Progress on regional and strategic partnerships for the Phase 2 trial [sec · filed 2025-11-07].
- Ability to secure additional financing to fund ongoing R&D and operations [sec · filed 2025-11-07].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run KAZIA THERAPEUTICS LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KAZIA THERAPEUTICS LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$3.5M
| Holder | Shares | Value |
|---|---|---|
| balyasny asset management l.p. | 193,114 | $1.4M |
| flputnam investment management co | 142,469 | $1.1M |
| royal bank of canada | 34,340 | $255K |
| barclays plc | 23,999 | $179K |
| raymond james financial inc | 15,749 | $117K |
| ubs group ag | 13,934 | $104K |
| rockefeller capital management l.p. | 12,700 | $94K |
| laird norton wetherby trust company, llc | 12,400 | $92K |
| qube research & technologies ltd | 10,608 | $79K |
| osaic holdings, inc. | 8,744 | $65K |
Showing top 10 of 16 institutional holders of KAZIA THERAPEUTICS LTD. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 3.6%
- Days to cover
- 1.4
- Shares short
- 408,115
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KZIA short interestFrequently asked questions
What is the AI investment thesis for KAZIA THERAPEUTICS LTD?
Kazia Therapeutics Ltd is a clinical-stage oncology company developing two small-molecule drug candidates, Paxalisib (PI3K/Akt/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor), with a going-concern uncertainty and limited cash resources.
Who is the CEO of KAZIA THERAPEUTICS LTD?
Dr. John Edwin Friend II, M.D. is the chief executive officer of KAZIA THERAPEUTICS LTD (KZIA).
Where is KAZIA THERAPEUTICS LTD headquartered?
KAZIA THERAPEUTICS LTD (KZIA) is headquartered in Sydney, NSW, Australia.
What therapeutic areas does KAZIA THERAPEUTICS LTD focus on?
KAZIA THERAPEUTICS LTD develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.